Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:

• Case: A woman in her late 60s with a germline BRCA2 mutation and heavily pretreated ovarian cancer receives weekly nab paclitaxel and relacorilant — Angeles Alvarez Secord, MD, MHSc (0:00)

CME information and select publications

Featuring perspectives from Prof Susana Banerjee, including the following topics:

• Case: A woman in her mid 50s with multiregimen-recurrent low-grade serous ovarian cancer and a KRAS G12V mutation who receives avutometinib/defactinib with response, asymptomatic creatine phosphokinase elevation and mild facial rash — Dr Stover (0:00)
• Case: A woman in her early 30s with recurrent metastatic low-grade serous ovarian cancer, originally offered hospice due to poor condition, who receives avutometinib/defactinib with an excellent response — Dr Hussein (7:58)
• Case: A woman in her late 30s with multiregimen-recurrent folate receptor alpha-positive low-grade serous ovarian cancer (HER2 IHC 2+) who receives mirvetuximab soravtansine — Dr Cobb (18:21)

CME information and select publications

Featuring perspectives from Prof Susana Banerjee, including the following topics:

• Overview of the biology and treatment of low-grade serous ovarian cancer (0:00)
• Mechanism of action of avutometinib/defactinib (10:16)
• RAMP 201 Trial: Avutometinib/defactinib in recurrent low-grade serous ovarian cancer (14:32)
• Ongoing clinical trials in low-grade serous ovarian cancer (27:57)

CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:

• Case: A woman in her mid 50s with BRCA1-mutated recurrent ovarian cancer receives mirvetuximab soravtansine — Ursula Matulonis, MD (0:00)

CME information and select publications

Featuring perspectives from Dr Nicoletta Colombo, Dr Gottfried E Konecny, Dr Alexander B Olawaiye and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:

• Case: A woman in her early 50s with a germline BRCA1 mutation and ovarian cancer experiences disease recurrence after completing olaparib/bevacizumab maintenance therapy — Professor Jonathan A Ledermann (0:00)

CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics:

• Case: A woman in her mid 60s with Stage II uterine carcinosarcoma treated with surgery followed by paclitaxel/carboplatin, whole-pelvic radiation and vaginal cuff brachytherapy — Dr Angeles Alvarez Secord (0:00)
• Case: A woman in her mid 50s with ovarian cancer and a genomic instability score of 50, folate receptor alpha 90%, HER2 IHC 2+, and BRCA1/2 wild-type disease treated initially with surgery, carboplatin/paclitaxel and maintenance olaparib/bevacizumab — Dr Ursula Matulonis (8:46)

CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics:

• Case: A woman in her mid 60s with metastatic serous endometrial carcinoma that is HER2 IHC 3+ who received first-line carboplatin/paclitaxel/trastuzumab and second-line trastuzumab deruxtecan — Ursula Matulonis, MD (0:00)
• Commentary: Role of HER2-directed therapy in the maintenance setting for patients with HER2-positive disease — Professor Jonathan A Ledermann (12:29)

CME information and select publications

Featuring perspectives from Dr Shannon N Westin and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:

• Introduction (0:00)
• Ovarian Cancer (2:22)
• Endometrial Cancer (37:48)

CME information and select publications